Propanc Biopharma, Inc. · NASDAQ:PPCB
Propanc Biopharma — Investor Presentation (June 2017)
38 slides from Propanc Biopharma's investor presentation, Jun 1, 2017
Slide 1: Investor Presentation
Investor Presentation @M Propane | sin. Biopharma, Inc. OTCQB: PPCH
Slide 2: Forward Looking Statement
Forward Looking Statement Any statements set forth above that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect ‘management's current expectations and involve certain risks and uncert
Slide 3: About Propanc
About Propanc * Propanc is a clinical stage biopharmaceutical company focused on developing new cancer treatments for patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers. * The Company has developed a formulation of anti-cancer compounds which exert a number of ef
Slide 4: PRP
Slide 5: Are there natural elements in our body that help fight cancer?
9 Are there natural elements in our body that help fight cancer? Yes: enzymes stimulate biological reactions in the body. Especially enzymes secreted by the pancreas, essential for digestion of proteins and fats. Pancreatic Enzyme Therapy: A story with promising PANCREATIC SECRETION j icati a @ Tryp
Slide 6: Mixture of two proenzymes
Mixture of two proenzymes, trypsinogen (T) & chymotrypsinogen (C) from bovine pancreas. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include ovarian and colorectal cancers. Have also shown efficacy in kidney, breast, brain, prostate, lung, liver, uterine and skin cancers.
Slide 7: PRP induces cell differentiation
(Cacod ells unteated(a)and teat (b- 4), 1n(b) numerous microvilli can be seen. Panels(c) and () show tight junction (arrow heads}, desmosomes (rw) andincrement in gheosen deposits (asterisk) PRP induces cell differentiation, converting cancerous cells into normal cells. Evidence showing colorectal &
Slide 8: How do we know pancreatic cancer cells are differentiated?
insulin glucagon insulinvgl How do we know pancreatic cancer cells are differentiated? PRP increases in number of insulin & glucagon secreting cells significantly , an important function of normal pancreas cells. Results show pancreatic cancer cells are differentiated post treatment. on in untreated
Slide 9: HUVEC cells grown in presence of PRP
HUVEC cells grown in presence of PRP at 2 different concentrations. Significantly inhibits blood vessel formation (A+C). Cells remain viable, post treatment (B). Blood yessel formation Ye | Pa on ® Pro; 3 - PRP PRP. (05x) (1x)
Slide 10: In Vivo Efficacy, Human Ovarian Cancer Cells in Nude Mice
In Vivo Efficacy, Human Ovarian Cancer Cells in Nude-Foxn1™ Mice, Day 21 Orthotropic Ovarian Tumours A2780, N = 12 Control Group (PBS) TIC: as significant (p<0.05) reduction in mean tumour wei: low-dose T/C (47.9% & 53.6%, respectively) compared with ® Propanc
Slide 11: In Vivo Efficacy, Mouse Pancreatic Tumor Cells in Mice
In Vivo Efficacy, Mouse Pancreatic Tumor Cells in CS57BL/6 Mice, Day 26 Orthotropic Pancreatic Tumours Pan 02, N = 10 Control Group (PBS) 350 al 4 Ss Aad ery a i 2 ae 150 T/C: 83.3/500 mg/kg ri ; 5 e = 20 50 ° . ’ , ° BS Tic ne e ry arses 833500 = imgihe) mgike) + There was significant (p<0.05) redu
Slide 12: Initial Safety Profile Evaluated
Initial Safety Profile Evaluated Group Test Article Treatment + 14 day, in vivo toxicity of Trypsinogen and 1 PBS SmU/keg, Lv. Chymotrypsinogen A, 1:6 ratio, daily repeated intravenous tail vein injection in rats, evaluated 2 Trypsinogen eye + All dose levels well tolerated. Ree + . a coe n 3 Chymot
Slide 13: Proenzymes labelled with IR-dye
Proenzymes labelled with IR-dye 800C W (NHS ester) infrared dye forming stable conjugate. Method developed to analyse movement and distribution of trypsinogen and chymotrypsinogen in blood plasma.
Slide 14: PK Profile Investigated
PK Profile Investigated * Movement of proenzymes in the i os blood. L a b * T&C share similar profiles. # * Peak conc. btw 5 min and lhr e ww a : < and T’ life 1.5hrs approx. iene py a bse i il 4 _— i © owe | 22 “ine pot one acct, ® Propanc
Slide 15: Compassionate Use Data — Patients
Compassionate Use Data — 46 Patients Patient Condition Life Expectancy? Survival? * 46 terminal patients (UK & AUS) Pancreas Carcinoma 2 8 administered two proenzymes plus sor A A amylase via suppository. Stomach Cancer 2 8 * 16 patients significantly exceeded Non basi Lnaetrerne Z 2 life expectancy
Slide 16: A New Frontier: Anti-Cancer Stem Cell Therapy
Slide 17: Conventional therapies kill replicating cancer cells
Conventional therapies kill replicating cancer cells, but deep inside tumors are cells that develop resistance, called cancer stem cells (CSCs). They are not killed by standard treatment & can remain dormant. They migrate to other organs & cause spreading of the tumor. To achieve total victory, we n
Slide 18: Cancer stem cells do not replicate
They do not replicate They are not killed by conventional therapies Tumor suppressor genes, like guardians, in anormal cell detect mutations and prevent malignancies, but are silenced in CSCs The EMT program is switched on, promoting metastasis, which is the main cause of patient death from cancer.
Slide 19: Epithelial Mesenchymal Transition (EMT)
Epithelial Mesenchymal Transition (EMT) ° EMT isa normal biological event during embryogenesis & organ development. ° Associated with wound healing & tissue repair. ¢ When turned on in CSCs, cancer cells lose contact with neighbouring cells and may potentially invade and metastasize, life threatenin
Slide 20: PRP is a patented approach
PRP is a patented approach that: Inhibits tumor metastasis and relapse. Complements conventional anti-cancer therapies. Is safe at specified dosages with minimal toxicity Is not cytotoxic
Slide 21: CSC Sphere Formation Blocked
CSC Sphere Formation Blocked ¢ An important feature of CSC’s is to from spheres when seeding new tumors. * PRP destroys primary spheres and suppresses ability of CSCs to form secondary spheres. 5 o 3 “0 Neuroblastoma x0 % 25 , 2 = 99 | Pancreatic 2B » aed 2 5 0 0 5 5 ot 0 BEG-CTL " BxPCLPRP ” SKNSHL
Slide 22: PRP Regulates the EMT
PRP Regulates the EMT PRP PROMOTES PRP HAS ANT-CANCER EFFECTS, BLOCKING TUMOR GROWTH AND Exerts a potent anti-EMT effect in CSCs ® Propanc
Slide 23: Key Signalling Pathways Altered
Key Signalling Pathways Altered * Reprograms CSC gene expression to reduce Bos s BxPC3 malignancy and a i invasiveness, so they die 1 og mcrr naturally. 5 ae i g % = “ PRE + Promotes expression of g ze - [ | z E-cadherin and ao % Pa decreases expression of 2 nee sas ia Tee N-cadherin & vimentin g *
Slide 24: PRP reverses the EMT
We have demonstrated (in vitro) that PRP dramatically reverses the EMT. By reversing the EMT, PRP: Stops tumor progression; Represses the CSC population. Potent indicators that PRP is an anti- CSC therapy.
Slide 25: Potential Over Competing Therapies
Potential Over Competing Therapies * Does not have adverse effects — \ safe for us. Ae F ° Does not target replicating cells, >_> i so will not affect healthy cells and . . will suppress undesirable effects y ) a ye. | from cancer. ( | F f * But, why not? Because PRP \ iy is ' ‘ regulates expression
Slide 26: Corporate Strategy
Corporate Strategy Future Landscape @® Propanc OTCQB: PPCH pepahecom
Slide 27: International R&D Partnerships
International R&D Partnerships UNIVERSITY OF BATH Joint IP ownership and Commercialization Agreement. Universidad de Jaén Universidad de Granada @ FIBAO_ Joint research collaboration: Drug discovery oncology program New compound screening Translational research Clinical development F as, In vivo eff
Slide 28: Propanc Innovation & Intellectual Property
Propanc Innovation & Intellectual Property * Six patent applications covering several important discoveries regarding proenzymes and their anti-cancer effects. ‘A pharmaceutical composition for treating Australia, Japan, Indonesia, Israel, New Granted Oct-22-2010 cancer comprising trypsinogen and/or
Slide 29: PRP Entering Pre-Commercialization Development Phase
PRP Entering Pre-Commercialization Development Phase * Successful scientific advice meeting with MHRA (UK), Apr, 2016. ° Current activities: 28 day safety toxicokinetic study completed GLP-compliant 28 day repeated dose toxicity study completed Development of bioanalytical animal and human assays un
Slide 30: Development Timelines
Development Timelines Non-Clinical Development IMP Manufacture Obtain Regulatory Approval for F.LH. Phase Ila Patient Trials
Slide 31: Month Financial Plan
12 Month Financial Plan * Complete IMP Manufacture and submit CTA for PRP. * Initiate drug discovery program for POP1. Act General & Administrative 1.50 Balance Sheet Restructure 2.00 Clinical Development (PRP): Bioanalyticals 0.25 IMP Manufacture 1.50 Regulatory (IMPD, CTA) 0.50 Drug Discovery (POP
Slide 32: PRP Manufacture for Human Use - Update
PRP Manufacture for Human Use - Update * IMP will consist of 2 proenzymes from natural sources, purified and polished. * Current status of activities: ° ° Isolation process for both proenzymes established and scaled up. Proenzymes extracted, precipitated and lyophilized, serving as starting material
Slide 33: Significant Market Opportunity
Significant Market Opp * 80% of ALL cancers are % Future Combined Markets in 2020, solid tumors: GBI Research ($$Billions) — Initially target pancreatic, ovarian & colorectal tumors. mcolorectal — 780,702 global deaths, combined, in 2012 (WHO). mpancreatic — $14B combined market segment by 2020 (GBI
Slide 34: Partnering/ Licensing Opportunity
Partnering/ Licensing Opportunity * Propanc is seeking a licensing or strategic partner * Worldwide Rights are available * The partner should have the following characteristics: * Ability to complete the required clinical trials for approval, in all indications ¢ Expertise with regulatory approval p
Slide 35: Drug Development & Clinical Expertise
Drug Development & Clinical Expertise Mr James Nathanielsz Dr Julian Kenyon Prof. Klaus Kutz Chief Executive Offic Chief Scientific Officer Chief Medical Officer + Director & CE.O, Oct ‘07 + Co-Founder & Director + 15 yrs. experience as consultant in Feb “08. Clinical Pharmacology & Safety + 20 yrs.
Slide 36: Medical and Scientific Advisory Board
Medical and Scientific Advisory Board Professor John Smyth Univ. of Edinburgh Professor Emeritus Medical Oncology & Honorary Assistant Principal Cancer Research Development, Univ. of Edinbur; Chair, Expert Advisory Group for Oncology & Hematology for the Commission of Medicines. Serves on the Expert
Slide 37: Increasing Shareholder Base with Upside Potential
Increasing Shareholder Base with Upside Potential Ticker: OTCQB:PPCH Status: Fully Reporting Shares (O/S): 3.66M Price*: $1.72 Mkt Cap*: $6.29M Ave Daily Vol. (3m): 18,634 52 Week Range: $8.00— 1.00 Clinical Comparisons: OMED = $148.24M, STML = $216.72M, VSTM =$78.61M
Slide 38: Thank You!
Thank You! May 2017 Consulting for Strategic Growth 1 Stanley Wunderlich 212-682-6300 swunderlich@cfsgl.com @ Propanc 302/6 Butler Street, Camberwell, Victoria, 3124, AUSTRALIA Biophatma, inc propane.com
Propanc Biopharma — Investor Presentation (June 2017) on 6ix